Book Review: Transhumanist Dreams and Dystopian Nightmares
By John Galloway,
BioNews
| 03. 11. 2013
Perhaps fortuitously, I started to read
Maxwell Mehlman's
book at the same time as
Roy Porter's 'A Short History of Madness'. It was then difficult not to muse on what
Jonathan Swift might have made of 'transhumanising scientists'. His satirising of scientists 'infected with lunacy' in the eighteenth century provides a hard to avoid parallel with Mehlman's very much not satirical account of biologists of the twentieth century.
Every school child now knows that molecular genetics is set to transform the world as we know it. Although exactly who 'we' are, is not specified; nor are we always told whether the transformation will be for good or ill. We can be reasonably certain though that most of the world's existing population will be dead before genetics' claims for medicine have any effect on them.
Read more...
Related Articles
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...
By Nick Paul Taylor, Fierce Biotech | 01.09.2026
Menlo Ventures has made a $16 million bet that the “baby KJ” custom CRISPR therapy success story is repeatable. The funding has enabled CRISPR co-inventor Jennifer Doudna, Ph.D., and baby KJ scientist Fyodor Urnov, Ph.D., to launch Aurora...
By David Cox, Wired | 01.05.2026
As he addressed an audience of virologists from China, Australia, and Singapore at October’s Pandemic Research Alliance Symposium, Wei Zhao introduced an eye-catching idea.
The gene-editing technology Crispr is best known for delivering groundbreaking new therapies for rare diseases, tweaking...